Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses glial fibrillary acidic protein (GFAP) as an emerging biomarker for multiple sclerosis (MS). Research looking at GFAP is still in earlier stages compared to other MS biomarkers, such as neurofilament light chain (NfL). Still, studies have suggested that GFAP may be better associated with progression independent of relapses. Therefore, combining both biomarkers may better predict the disease course. However, other studies have not found similar findings, and the role of GFAP as a biomarker in MS remains under active investigation. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.